
Radiance Biopharma To Present At The Microcap Conference 2025
– Radiance Biopharma, a clinical stage biotechnology company developing next generation Antibody Drug Conjugates (ADCs), announced it will present at the Microcap Conference, being held January 28-30, 2025, in Atlantic City, N.J.
Management will deliver a corporate presentation and engage in meetings with institutional and individual investors to discuss the company's development, growth strategy, and investment opportunities.
Microcap Conference Presentation
Venue: the Borgata Hotel Spa & Casino in Atlantic City, NJ.
Date: Thursday, January 30, 2025
Time: 2:00 pm ET
About Radiance Biopharma
Radiance is a clinical stage biotechnology company developing next generation Antibody Drug Conjugates (ADCs) for the treatment of cancer. RB-164, is a 'Best in Class', anti-ROR-1 ADC, for the treatment of liquid and solid tumors. RB-201, is a 'First in Class' anti- HER2/TROP2 Bispecific ADC, utilizing next generation tandem linker-payload technology, for the treatment of solid tumors.
Contacts For more information, please visit Contact us at ... Office Tel. 617.621.7143
Robert Brooks
Radiance Biopharma
6176217143 ext.
email us here
Visit us on social media:
LinkedIn
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Comments
No comment